With central banks signaling that interest rates may stay higher for longer, investors face a tougher backdrop for companies that rely on cheap capital and short term momentum. Founder led businesses often take a different path. Leaders with significant skin in the game tend to think in decades, not quarters. This article highlights 3 founder led stocks from our screener that show how this ownership mindset can shape long term opportunity.
The three founder led stocks in this article are only a small sample, and the full screen surfaced 85 more companies with equally compelling ownership stories and business narratives that are not covered here. To go deeper, head straight into the Founder-Led Companies screener to identify, filter and analyze the founder led businesses that best fit your own conviction and risk profile.
Macquarie Technology Group (ASX:MAQ)
Overview: Macquarie Technology Group is an Australian provider of cloud services, data centres, cybersecurity and telecoms for corporate and government customers, with founder led executives still closely involved in steering its cloud and data centre strategy. Its Cloud Services and Government segment, which covers hosted voice, private and hybrid cloud, Azure support and managed security, is a key focus area, but the group remains diversified across data centres and telecom.
Operations: Macquarie Technology Group generates A$235.6 million of revenue from Cloud Services and Government, A$105.2 million from Telecom and A$87.0 million from Data Centres, with virtually all of its A$390.0 million in revenue coming from Australia.
Market Cap: A$1.4b
Macquarie Technology Group gives you a founder led cloud, data centre and telecom platform that is already serving government and enterprise clients, yet still appears to be in an investment phase, with decisions being made by leaders with long histories at the company. Revenue sits at about A$390.0 million, while net profit margins of 8.2% and a recent decline in earnings and return on equity show that the push into cloud infrastructure and security involves trade offs. The stock trades on a high P/E, which indicates that investors already expect a lot from this leadership team. For investors assessing whether that founder commitment justifies the valuation and margin pressure, this is a business that may warrant a closer look.
Macquarie Technology Group is priced for big expectations, yet current margins and returns look out of sync with that premium. Read the DCF valuation analysis for Macquarie Technology Group to see what the market might be missing.
Pro Medicus (ASX:PME)
Overview: Pro Medicus is a founder led healthcare software company whose Visage 7 Enterprise Imaging Platform and Visage RIS/PACS systems help radiologists and clinicians load, view and interpret complex medical images faster, supported by mobile and diagnostic apps like Visage Ease and Visage Ease Pro across hospitals in Australia, Europe and North America.
Operations: Pro Medicus generates A$261.7 million in revenue from a single integrated segment producing software applications for the health care industry, with reported sales concentrated in Australia and North America.
Market Cap: A$18.96b
Pro Medicus may be of interest to investors who focus on founder led businesses where a single flagship product defines much of the story. Its Visage platform has reportedly become central to some radiology departments, with doctors requesting it in their employment contracts. This level of integration into clinical workflows helps explain reported net profit margins above 50% and resilient renewal rates. At the same time, the stock trades on a very high P/E, non cash earnings are flagged as significant and all liabilities come from higher risk funding sources, so any slowdown in growth or contract wins could affect sentiment. For those considering whether this premium is supported by founder involvement and product positioning, there are several factors to examine beyond the headline numbers.
Pro Medicus combines very high margins with a heavy valuation that many investors focus on, while overlooking key details in its contracts and funding mix. Get the analysis report for Pro Medicus for the twist that could change how you see the stock
Mesoblast (ASX:MSB)
Overview: Mesoblast is an Australian biotech company focused on regenerative medicine, using mesenchymal lineage cell therapies such as remestemcel L/r and Ryoncil to address severe inflammatory and cardiovascular diseases. These flagship founder guided programs anchor its founder led identity even as it develops a wider pipeline of cell based treatments and partnerships.
Operations: Mesoblast currently generates about US$120 million in revenue from the development and commercialization of its allogeneic cellular medicines platform.
Market Cap: A$3.19b
Mesoblast attracts interest because its founder led approach is most visible in how remestemcel L/r and Ryoncil have been pushed from lab concept into late stage trials, regulatory designations and global partnerships, backed by more than 1,100 patents and commercial scale manufacturing. Ryoncil is already approved in the U.S. for pediatric steroid refractory acute GvHD, with reported product net sales of US$11.3 million and broad payer coverage. The company still reports a loss of US$57.5 million and relies on higher risk external funding. Investors may consider how potential label expansions, new indications and the chronic low back pain and heart failure programs could influence the earnings profile, while weighing founder driven ambition against execution, financing and competitive risks that are described as still unsettled as of 2026.
Mesoblast’s cell therapy story is already significant, yet the real intrigue lies in how future label expansions and new indications could reshape expectations. Review the analyst forecasts for Mesoblast to see what the market might be glossing over.
Seeking Alternatives Beyond Founder Led Stocks
Fresh ideas can move fast. New themes gain momentum, then get caught by the crowd. Use these under the radar lists while the information is still sharp and consider your options carefully.
- Look for resilient income plays by scanning the curated 9 dividend fortresses that aim to maintain cash flows while others focus on short lived stories.
- Identify early AI momentum while it is still under the radar by tracking the hand picked 74 profitable AI stocks that aren't just burning cash already turning revenue into earnings.
- Review opportunities in infrastructure by checking the focused 38 power grid technology and infrastructure stocks that highlights businesses involved in critical grid upgrades.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com